We recently reported an internal tandem duplication of the receptor-type tyrosine kinases (RTKs), 8, 9 ses were also performed to reveal the time when the mutation duplication transformed to overt leukemia within a few months.
This study included 58 patients with MDS and 34 patients with overt leukemia showing trilineage myelodysplasia. The details of these 92 adult patients, whose marrow cells were Introduction karyotyped in our laboratory, are shown in Table 1 . The diagnosis was made according to the French-American-British Myelodysplastic syndrome (MDS) is an acquired hematopo-(FAB) classification 1, 17 and the criteria for AML with trilineage ietic disorder characterized by impaired hematopoiesis clinidysplasia without preleukemic phase (AML/TMDS) proposed cally manifested as peripheral cytopenia, morphological dysby Brito-Babapulle et al. 3 Patients with therapy-related AML plasia and a possible conversion to overt leukemia. 1, 2 In were those who had received chemo-and/or radiotherapy for addition, acute myeloid leukemia (AML) with trilineage myeprimary diseases of solid tumors or hematologic malignancies. lodysplasia (AML/TMDS) 3 and most of the therapy-related leukemias also display dysplastic morphologies in three lineages of the bone marrow cells and thus originates from a single Screening for FLT3 mutation pluripotent stem cell. Chromosomal abnormalities and several molecular alterations including mutational activation of protoGenomic DNA was extracted from bone marrow samples by oncogenes and inactivation of tumor suppressor genes are standard procedure and amplified by PCR using a set of 11F reported to play certain roles in the development of MDS and and 11R primers as described in the previous report. 7 This set subsequent progresion to acute leukemia. [4] [5] [6] Although genetic of primers amplifies the whole exon 11 encoding for nearly aberrations in MDS have been studied over the last decade, all the juxtamembrane (JM) and the small part of the first tyrothe mechanisms of pathogenesis of MDS and related disorders sine kinase (TK1) domains. 9, 18 The products were resolved on showing myelodysplasia are not completely clarified.
2% agarose gel (FMC, Rockland, ME, USA). Amplification of We recently demonstrated an internal tandem duplication exons 11 to 12 using an 11F/12R primer combination was as a somatic mutation of the flt3 receptor gene (FLT3) in 17% also carried out to confirm the abnormal bands. 
Expression of altered FLT3 gene
In cases of FLT3 mutation, mutant allelic expression was examined whenever possible by reverse transcription PCR (RT-PCR) with a set of R5 and R6 primers, 7 which completely cover the transmembrane domain (TM) and the JM domain of the FLT3 gene. The integrity of sample RNAs was checked by amplifying a 210-bp ␤-actin fragment.
Further genetic analyses site. 19 Similarly, codon 13 of N-RAS was studied using nested primers introducing a novel PfIMI restriction site. 19 PCRmediated single-strand conformation polymorphism (SSCP) patients with FLT3 duplication were intact in the last 11 carboxyl-end amino acids of exon 11. analysis for N-RAS codon 61 and exons 5 to 8 of the TP53 gene were also performed as described in the previous Using the RT-PCR method, altered FLT3 mRNA proved to be expressed in all five patients whose marrow cells were studies. 19, 20 available for total RNA extraction ( Figure 3 ). Duplicated fragments in mRNA were completely identical for the altered genomic sequence of each patient, and the wild-type length Results mRNA was simultaneously expressed in all patients. Longitudinal analysis on FLT3 mutation during the disease Tandem duplication of the FLT3 gene course was carried out in cases 601 and 701. Case 601 was included in the previous series of patients as case M810 and Among 92 patients examined, seven (8%) had a longer PCR product as well as a product of germline size at exon 11 proved to harbor an internal tandem duplication of 26 bp with a 4-bp insertion in exon 11 at the time of diagnosis of ( Figure 1 , Table 1 ). Sequencing of the aberrant PCR product revealed a simple tandem duplication of exon 11 in cases 412 AML/TMDS. 7 The latest marrow sample in this patient showed an unexpectedly longer amplicon as well as the previous one (nt 1735-1794: 60 bp), 533 (nt 1744-1803: 60 bp), 601 (nt 1738-1824: 87 bp) and 612 (nt 1789-1815: 27 bp) (Figure 4) , and the sequencing of the longer one revealed the 87-bp tandem duplication. This latest duplicated fragment (Figure 2 ). Since the duplicated part of the genomic sequence started at the first letter of each coding triplet, altered traninvolved the same part of the previous one (22 bp), although both the starting and ending nucleotides of duplication were scripts in these four could be strictly in-frame. In cases 609 and 701, the first amino acid of the duplicated region was different to each other (Table 2, Figure 2 ). Case 701 showed abnormal length only in the last material obtained at the time deduced to substitute Arg (CGC) to Gly (GGC) and Ile (ATT) to Lys (AAT), respectively. Case 619 showed a tandem dupliof autopsy. Former materials included at the time of onset of therapy-related leukemia and 31-or 2-month earlier samples cation of 29 bp with a 4-bp insertion, resulting in an insertion of Pro (CCG). Deduced amino acid sequences of all seven showed only a product of germline size (Figure 4 ).
Figure 4
Longitudinal analyses of genomic DNA from cases 601 and 701. PCR products of 225 bp for exon 11 to 12, using an 11F/12R primer combination, were resolved on 2% agarose gel. Case 601 showed a 30 bp longer product of FLT3 throughout the clinical course, and also an 87 bp longer one at the terminal stage (18 months after diagnosis). Case 701 harbored a 36 bp longer product only in the last sample obtained when he died. Wild type designates normal genomic DNA samples, as mentioned in Figure 1 .
Clinical characteristics and other genetic aberrations in patients with FLT3 mutation Table 2) . Two of these seven had tution of deduced amino acid. Case 601 harbored an independent MDS and showed leukemic transformation 1 and 3 months duplication at the last sample from the former one found at diagnosis, after the detection of the FLT3 duplication, respectively. of which sequence was previously reported as M301. 7 Among the other five with overt leukemia, two had AML derived from MDS, whose DNA samples were not obtained at MDS phase, and the other two had AML/TMDS without a significant preleukemic phase. The remaining one had therapy-related AML with a previous history of chemotherapy for malignant lymphoma.
Cytogenetic analysis revealed abnormal karyotypes in all six patients examined successfully, except case 533 with concomitant marrow fibrosis. Of these six, four showed a loss of chromosome 5, 7 and/or 12, which were nonrandom chromosome alterations in myelodysplasia. 21, 22 Another patient (case 619) had a t(3;12)(q26;p13), which was recently reported to be a rare but recurrent abnormality in myelodysplasia. 23 No one showed an abnormality involving band 13q12 where the FLT3 gene is located. A point mutation of the N-RAS gene was found in three patients at codons 12 or 13. Case 601 harbored a codon 13 mutation at the time of diagnosis and another codon 12 mutation emerged during his disease course at the refractory stage, concomitantly with karyotypic evolution.
24 TP53 mutation was identified in two patients. Case 612, whose clinical course and karyotype have been he survived 22 months after the diagnosis. 
Discussion
Two independent FLT3 duplications were detected in one patient with AML/TMDS (case 601). As we demonstrated previously, 7, 24 this patient had an abnormal karyotype and an NOur previous analysis revealed internal tandem duplication of the FLT3 in five of 30 patients with AML. 7 Accordingly, we RAS mutation, in addition to FLT3 duplication at the time of diagnosis of M4 with trilineage dysplasia. When leukemic found 12 duplications in 11 patients (case 601 had two duplicated segments) in the previous and present studies. Sequenblasts acquired the clinical manifestations of growth advantage and drug resistance, he showed the second N-RAS cing of the aberrant amplicon revealed the simple tandem duplications in seven, involving nine to 29 coding triplets. The mutation, concomitantly with a karyotypic evolution. Consequently, leukemic involvement of meninges, lymph nodes and other four harbored an insertion or a substitution of one amino acid concomitantly with a duplication (case M810 in the preskin emerged, and he died of meningeal leukemia 22 months after disease onset. At this terminal stage, leukemic cells vious report and cases 609, 619 and 701 in the present report), and the remaining one involved intron 11 and exon revealed the second FLT3 tandem duplication of 87 bp, which had not been detected in any samples obtained during his 12 as well as exon 11 (case M155 in the previous report). These genetic alterations eventually occur in-frame, and disease course. This case may indicate a close correlation between the disease progression and the accumulation of gendeduced amino acid sequences of all patients were intact in two TK domains with nine to 29 inserted amino acids etic aberrations involving the FLT3 gene. Another patient (case 701) also showed a FLT3 duplication upstream. This finding supports the hypothesis that lengthened FLT3 protein with intact TK domains gain or lose certain funcfor the first time when he died of therapy-resistant leukemia. Because both of these patients received multi-drug therapy tions of cell proliferation through inserted amino acids, resulting in growth advantage of leukemic cells.
before the late appearing FLT3 duplication, we presume the duplications were induced by chemotherapy. It is of great In this study, we identified internal tandem duplications of the JM/TK1 domains of the FLT3 receptor gene in seven of 92 interest that possible models for the formation of this type of aberration are based on single-or double-stranded breaks as patients with myelodysplasia. The incidence of the mutation in overt leukemia (15%) was higher than that in MDS (3%) Chia et al 26 hypothesized in their study of in-frame tandem duplication of the Adh gene in Drosophila melanogaster. We and similar to our reported incidence in AML. 7 Two MDS patients with FLT3 duplication progressed to overt leukemia postulate that tandem duplications in genomic sequence were induced at relatively higher incidences than point mutations a few months after diagnosis. These findings suggest FLT3 mutation is closely associated with blast cell proliferation, in certain genes by exposure to exogenous mutagens. The present study found that the accumulation of genetic resulting in leukemic transformation from preleukemic myelodysplasia. The existence of two patients with leukemia showevents clearly correlates with leukemic transformation from MDS and subsequent disease progression of this ill-managed ing late appearance of the mutation at the therapy-resistant phase during the disease course may confirm this association. myeloid malignancy. Although a significant number of patients with myelodysplasia show a normal karyotype and Moreover, based on the fact that FLT3 duplications became detectable after the emergence of an N-RAS mutation (case no molecular alterations, further studies on the genetic events in MDS and related diseases may resolve the comprehensive 601) or a TP53 mutation (case 701), we postulated that tandem duplications of the FLT3 were identified as the latest mechanism of the development and progression of preleukemia and leukemia with myelodysplasia. We conclude that the genetic event among the genetic alterations examined in this series of patients.
duplication of the FLT3 gene is one of the possible genetic
